Sterling Investment Advisors, Ltd. Annovis Bio, Inc. Transaction History

Sterling Investment Advisors, Ltd.

  • $334 Million
  • Q1 2024

A detailed history of Sterling Investment Advisors, Ltd. transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Sterling Investment Advisors, Ltd. holds 34,374 shares of ANVS stock, worth $225,149. This represents 0.12% of its overall portfolio holdings.

Number of Shares
34,374
Previous 34,374 -0.0%
Holding current value
$225,149
Previous $642,000 36.29%
% of portfolio
0.12%
Previous 0.21%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023
BUY
$11.95 - $16.31 $11,950 - $16,309
1,000 Added 3.0%
34,374 $491,000
Q1 2023

Apr 25, 2023
BUY
$12.33 - $22.1 $11,097 - $19,890
900 Added 2.77%
33,374 $514,000
Q3 2022

Nov 03, 2022
BUY
$10.26 - $21.81 $56,430 - $119,955
5,500 Added 20.39%
32,474 $445,000
Q2 2022

Aug 05, 2022
BUY
$8.61 - $13.87 $68,880 - $110,960
8,000 Added 42.16%
26,974 $306,000
Q1 2022

May 03, 2022
BUY
$11.84 - $19.78 $53,280 - $89,010
4,500 Added 31.09%
18,974 $253,000
Q3 2021

Nov 09, 2021
SELL
$30.95 - $120.97 $188,795 - $737,917
-6,100 Reduced 29.65%
14,474 $460,000
Q2 2021

Jul 29, 2021
SELL
$21.55 - $96.1 $239,291 - $1.07 Million
-11,104 Reduced 35.05%
20,574 $1.76 Million
Q1 2021

May 04, 2021
SELL
$8.15 - $38.44 $154,116 - $726,900
-18,910 Reduced 37.38%
31,678 $884,000
Q4 2020

Jan 21, 2021
SELL
$4.36 - $7.54 $1,962 - $3,393
-450 Reduced 0.88%
50,588 $381,000
Q3 2020

Oct 26, 2020
BUY
$3.84 - $6.78 $195,985 - $346,037
51,038 New
51,038 $245,000

Others Institutions Holding ANVS

# of Institutions
52
Shares Held
1.2M
Call Options Held
779K
Put Options Held
1.77M
View Full List

About Annovis Bio, Inc.

ANVS Quotes by TradingView
  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $53.5M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Sterling Investment Advisors, Ltd. Portfolio

Follow Sterling Investment Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sterling Investment Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sterling Investment Advisors, Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email